The short version of anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Mechano growth factor (MGF, IGF-IEc) is a naturally occurring 24-amino acid peptide which is the C-terminal fragment derived from enzymatic cleavage of insulin-like growth factor 1 (IGF-1). It is expressed during muscle repair following physical activity, and has anabolic effects. This has led to illicit use by athletes leading to MGF being banned by the World Anti-Doping Association. At least one research paper raised concerns about the potential carcinogenicity of this compound.
Direct regulation of translation is less prevalent than control of transcription or mRNA stability but is occasionally used. Inhibition of protein translation is a major target for toxins and antibiotics, so they can kill a cell by overriding its normal gene expression control. Protein synthesis inhibitors include the antibiotic neomycin and the toxin ricin.
Amy Walter, editor of the nonpartisan The Cook Political Report, also argued that the electoral environment was inherently difficult for Harris because the top issue for voters was inflation during the Biden-Harris administration. Ronald Brownstein of The Atlantic, who spoke with members of Harris's campaign, argued that the extent of Biden's unpopularity and public discontent with the economy proved too much for Harris to overcome. Brownstein compared the election to the 1968 presidential election (when unpopular incumbent Lyndon B. Johnson withdrew from the race and Vice President Hubert Humphrey lost to Richard Nixon) and the 1980 presidential election (when unpopular incumbent Jimmy Carter lost to Ronald Reagan due to stagflation and the 1970s energy crisis). Members of Harris' campaign stated after the election that their internal polling never showed Harris ahead of Trump and they did not believe that Harris was the favorite to win the election. David Plouffe, a senior campaign advisor to Harris, claimed that even making the race competitive was a win for Harris' staff. The opportunity to elect Harris as the first female U.S. president proved to be less important to voters than issues like the economy and immigration. Results of VoteCast, as reported by Fox News, find that 13% of voters chose "the fact that Kamala Harris would be the first female president" as the single most important factor to their vote. Even so, polls have shown that voters support backing a female candidate while also acknowledging the challenges they might face on the campaign trail.
Sources: en.wikipedia.org
=== Further discoveries of the therapeutic potential of GLP-1 at University of Toronto === In 1987 Drucker returned to Toronto, taking on the position of Assistant Professor of Medicine at the University of Toronto and continuing his research on the glucagon-like peptides while also working as a physician. In 1996, Drucker was one of several investigators who demonstrated that GLP-1 reduced food intake in preclinical studies. Notably, the experiments in the Drucker lab demonstrated that this action of GLP-1 in the brain required the functional canonical GLP-1 receptor. Drucker, together with colleagues at Tufts Universities, filed multiple patents describing the utility of targeting the DPP-4 enzyme, and published studies demonstrating that genetic or chemical inactivation of DPP-4 prevented degradation of GLP-1 and GIP, supporting the development of DPP-4 inhibitors for the treatment of type 2 diabetes. In all, Drucker's discovery science has led to 33 issued US patents supporting translational drug development efforts in the field of peptide based therapeutics. Collectively, the body of work from multiple investigators and companies led to the development of two leading classes of diabetes medications: GLP-1 receptor agonists and DPP4 inhibitors.
lipoprotein Any water-soluble protein to which one or more lipid molecules are attached by covalent bonding to amino acid residues. Many classes of lipids can be conjugated to proteins, including triacylglycerols, cholesterols, and phospholipids. Compare proteolipid.
=== Cellular energy production === The conversion of ATP to ADP is the principal mechanism for energy supply in biological processes. Energy is produced in cells when the terminal phosphate group in an ATP molecule is removed from the chain to produce adenosine diphosphate (ADP) when water hydrolyzes ATP: ATP + H2O → ADP + HPO42- + H+ + energy However, removing a phosphate group from ADP to produce adenosine monophosphate (AMP) also produces extra energy.
=== Boers retreat === The set-piece period of the war now largely gave way to a guerrilla war, but one final operation remained. President Kruger and what remained of the Transvaal government had retreated to eastern Transvaal. Roberts, joined by troops from Natal under Buller, advanced against them, and broke their last defensive position at Bergendal on 26 August. As Roberts and Buller followed up along the railway line to Komatipoort, Kruger sought asylum in Portuguese East Africa (modern Mozambique). Some dispirited Boers did likewise, and the British gathered up much war material. However, the core of the Boer fighters under Botha easily broke back through the Drakensberg Mountains into the Transvaal highveld after riding north through the bushveld. As Roberts's army occupied Pretoria, the Boer fighters in the Orange Free State retreated into the Brandwater Basin, a fertile area in the south-east of the Republic. This offered only temporary sanctuary, as the mountain passes leading to it could be occupied by the British, trapping the Boers. A force under General Archibald Hunter set out from Bloemfontein to achieve this in July 1900. The hard core of the Free State Boers under De Wet, accompanied by President Steyn, left the basin early. Those remaining fell into confusion and most failed to break out before Hunter trapped them.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.